The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients
Status:
Not yet recruiting
Trial end date:
2035-06-01
Target enrollment:
Participant gender:
Summary
Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead
to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure
while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution
0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of
glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye
redness, intraocular pressure, and eyelid position in patients with glaucoma who are already
using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.